[go: up one dir, main page]

WO2009070917A1 - Composition pharmaceutique orale pour le traitement de la barythymie - Google Patents

Composition pharmaceutique orale pour le traitement de la barythymie Download PDF

Info

Publication number
WO2009070917A1
WO2009070917A1 PCT/CN2007/003388 CN2007003388W WO2009070917A1 WO 2009070917 A1 WO2009070917 A1 WO 2009070917A1 CN 2007003388 W CN2007003388 W CN 2007003388W WO 2009070917 A1 WO2009070917 A1 WO 2009070917A1
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
group
acid
present
raw material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2007/003388
Other languages
English (en)
Chinese (zh)
Inventor
Zuoguang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/CN2007/003388 priority Critical patent/WO2009070917A1/fr
Publication of WO2009070917A1 publication Critical patent/WO2009070917A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the invention relates to an oral medicine for treating depression caused by glycyrrhizic acid or glycyrrhetic acid, in particular to prevent side effects such as strong vomiting.
  • Depression is a common disease. According to statistics, about 25% of women in the general population have experienced depression during their lifetime, and about 10% of men have experienced depression (Zhang Chunxing: Modern Psychology) . Data from the World Health Organization (WHO): The incidence of depression in the world is about 11%. There are currently about 340 million people with depression in the world, and this number is still on the rise. The survey found that in the next 20 years, depression It will rise to the second most common disease in the world.
  • WHO World Health Organization
  • the antidepressant drugs are mainly based on Prozac, Serote, Zoloft, etc. (SS-, SNRI, NDRI, etc. 5-HT, NE, DA reuptake inhibitors), and the mechanism of action is Increase the content of serotonin and other components in the human nervous medium to alleviate the symptoms of depression.
  • anti-depressant drugs that have been asked have different degrees of side effects, such as: increased suicide rate, headache, dizziness, dizziness, insomnia, lethargy, deafness, dry mouth, anorexia, increased appetite, weight gain, blood pressure rise, Gastrointestinal discomfort, nausea, nausea, vomiting, indigestion, diarrhea, constipation, lower extremity pain, skin rash, trembling, cramps, sweating, edema, loss of libido, sexual incompetence, etc.
  • anti-depressant drugs such as Prozac have become a serious concern in the society.
  • the US Food and Drug Administration (FDA) in 2004 asked the pharmaceutical companies to relabel the main 32 anti-depressants on the market.
  • FDA US Food and Drug Administration
  • an object of the present invention is to provide an oral drug for treating depression caused by a raw material containing glycyrrhizic acid or glycyrrhetic acid, in particular, a new technique which does not cause side effects such as strong vomiting. Program.
  • the solution of the medicament of the invention is the scar of the research and exploration by the inventors, and the anti-depressant medicine is prepared by using glycyrrhizic acid or glycyrrhetinic acid as raw materials according to the pathology and pharmacological mechanism and experiment of modern medical treatment of depression, after animal experiment. Proven to have significant anti-depressant function.
  • Licorice is a medicinal material commonly used in traditional Chinese medicine and dietary supplement diets for thousands of years. In the long-term clinical treatment of traditional Chinese medicine and daily human consumption, there has not been a case of vomiting caused by taking licorice, so the inventor proposed glycyrrhizic acid. Or glycyrrhetinic acid is used as a raw material to make new technical solutions for treating depression drugs to improve the defects produced in the prior art.
  • the drug of the present invention differs from the conventional antidepressant drug rolita, which is a post-receptor mechanism of action, in that it can simultaneously initiate cyclic adenosine monophosphate by inhibiting cAMP phosphodiesterase (CAPD).
  • cAMP in order to achieve anti-') effect, can avoid side effects such as strong vomiting caused by taking loliprazol.
  • Biological activity Inhibition of cAMP citrate diesterase (CAPD) with a median effective dose (ED50) of 1.9 10 -4 .
  • the conversion rate of glycyrrhizic acid into glycyrrhetinic acid in the human body is almost 100%, and the glycyrrhetinic acid which is more fat-soluble than glycyrrhizic acid can enter the brain through the blood-brain barrier, glycyrrhizic acid inhibits CAPD and has anti-depression effect. It is carried out by in vivo conversion to glycyrrhetinic acid, and therefore, the medicament of the present invention can be processed by using glycyrrhizic acid or glycyrrhetinic acid as a raw material.
  • the present invention is an oral drug for treating depression which is made of a raw material comprising glycyrrhizic acid or glycyrrhetinic acid.
  • the oral medicament of the present invention can be processed into a tablet, a capsule, a powder, a tablet, a powder, a solution, a micro-dip, a suspension, an emulsion, a granule, a pill, a pill, etc.
  • the dosage form of the oral administration of the present invention once a day is prepared from a raw material comprising 6 to 240 mg of glycyrrhizic acid or glycyrrhetinic acid; more preferably, it comprises 12 to 120 mg of glycyrrhizic acid. Or made of raw materials of glycyrrhetinic acid.
  • the oral dosage form of the oral administration of the present invention is prepared from a raw material comprising 3 to 120 mg of glycyrrhizic acid or glycyrrhetinic acid; more preferably, it comprises 6 to 80 mg of licorice.
  • a raw material comprising 3 to 120 mg of glycyrrhizic acid or glycyrrhetinic acid; more preferably, it comprises 6 to 80 mg of licorice.
  • the dosage form of the oral drug of the present invention taken three times a day is made of a raw material comprising 2 to 80 mg of glycyrrhizic acid or glycyrrhetinic acid; more preferably, it comprises 4 - 60 mg of glycyrrhizic acid. Or made of raw materials of glycyrrhetinic acid.
  • the oral dosage form of the present invention is administered four times a day, and is prepared from a raw material comprising 1.5 - 60 mg of glycyrrhizic acid or glycyrrhetinic acid; more preferably, it comprises 3 to 40 mg of licorice. Made from raw materials of acid or glycyrrhetinic acid.
  • the oral medicament of the present invention comprises a pharmaceutically acceptable carrier or additive.
  • the invention further comprises a health food and a nutrient.
  • the oral medication for treating depression as described in the specification and the scope of the present application is the core of the object of the present invention.
  • those skilled in the art can according to the theory of traditional Chinese medicine or related modern pharmacology.
  • the above drugs are routinely added or subtracted or replaced with other traditional Chinese medicine active ingredients (such as Polygala, Bupleurum, Licorice coumarin, etc.).
  • Such conventional addition and subtraction cultivation and replacement of the traditional Chinese medicines of other CAPD inhibitors having similar or identical mechanism of action or corresponding active ingredients are common technical activities of those skilled in the art, and thus all of them are in the present invention.
  • FIG. 1 is a schematic flow chart of a method for preparing a medicament of Example 1 of the present invention.
  • Fig. 2 is a flow chart showing the process of preparing the medicament of the embodiment 2 of the present invention.
  • Fig. 3 is a schematic flow chart showing the process of preparing the drug of the third embodiment of the present invention.
  • Fig. 4 is a flow chart showing the process of preparing the drug of the fourth embodiment of the present invention.
  • Fig. 5 is a flow chart showing the process of preparing the drug of the fifth embodiment of the present invention.
  • Fig. 6 is a flow chart showing the process of preparing the drug of the sixth embodiment of the present invention. Preferred embodiment of the invention
  • the present invention is primarily directed to the preparation of the medicaments of the present invention in combination with the features of the present invention by methods well known to those skilled in the art.
  • the following examples are merely illustrative of the invention and are not intended to limit the invention.
  • the present invention particularly proposes the following technical solutions.
  • the raw material for treating depression is treated by the raw material containing glycyrrhizic acid or glycyrrhetinic acid.
  • the invention comprises the raw material containing glycyrrhizic acid or glycyrrhetinic acid, and is processed into the tablet, the capsule, the powder, the tablet, the powder, the solution, the microcapsule, the suspension, the emulsion and the granule for treating depression.
  • Any of the pharmaceutically acceptable oral dosage forms such as agents, pills, pills, and the like.
  • the preparation of the invention is prepared by using a raw material containing 6 to 240 mg of glycyrrhizic acid or glycyrrhetinic acid in a daily dosage form; more preferably, it is made of a raw material containing 12 to 120 mg of glycyrrhizic acid or glycyrrhetinic acid.
  • the medicament of the present invention is administered in a dosage form once a day.
  • the medicine of the present invention is prepared by using a raw material containing 3 to 120 mg of glycyrrhizic acid or glycyrrhetinic acid twice daily; more preferably, it is made of a raw material containing 6 - 80 mg of glycyrrhizic acid or glycyrrhetinic acid.
  • the medicament of the present invention is administered in a dosage form twice daily.
  • Option 5 :
  • the preparation of the invention is prepared by using a raw material containing 2 to 80 mg of glycyrrhizic acid or glycyrrhetinic acid in a dosage form which is taken three times a day; more preferably, it is made of a raw material containing 4 to 60 mg of glycyrrhizic acid or glycyrrhetinic acid.
  • the preparation of the invention is prepared by using a raw material containing 1.5 - 60 mg of glycyrrhizic acid or glycyrrhetinic acid in a dosage form of four times a day; more preferably, it is made of a raw material containing 3 to 40 mg of glycyrrhizic acid or glycyrrhetinic acid.
  • the drug of the present invention is administered in a dosage form that is taken four times a day.
  • the oral medicament of the present invention may contain a pharmaceutically acceptable carrier or additive.
  • the invention described in the present invention can also be used to make health foods and nutrients.
  • glycyrrhizic acid is extracted from licorice as raw material, or directly prepared by using glycyrrhizic acid or glycyrrhetinic acid as raw material, and processed into the present invention for treating depression Oral medication.
  • the raw material containing glycyrrhizic acid or glycyrrhetinic acid is processed into a tablet, a capsule, a powder, a tablet, a powder, a solution, a micro-tank, and the like for treating depression in the present invention.
  • Any of the pharmaceutically acceptable oral pharmaceutical dosage forms such as suspensions, emulsions, granules, pills, pills, and the like.
  • a raw material containing 6 to 240 mg of glycyrrhizic acid or glycyrrhetinic acid is processed into a dosage form of the present invention; more preferably, it contains 12 to 120 mg of glycyrrhizic acid or
  • the raw material of glycyrrhetinic acid is prepared into a medicament of the present invention in a dosage form which is taken once a day.
  • Method four According to the GMP pharmaceutical standard method, a raw material containing 3 to 120 mg of glycyrrhizic acid or glycyrrhetinic acid is processed into a dosage form of the present invention which is administered twice a day; more preferably, it contains 6 to 80 mg of glycyrrhizic acid. Or a raw material of glycyrrhetinic acid, which is prepared into a medicament of the present invention in a dosage form which is administered twice a day.
  • a raw material containing 2 to 80 mg of glycyrrhizic acid or glycyrrhetinic acid is processed into a dosage form of the present invention which is administered three times a day; more preferably, it contains 4 to 60 mg of glycyrrhizic acid or
  • the raw material of glycyrrhetinic acid is prepared into a medicament of the present invention in a dosage form which is administered three times a day.
  • a raw material containing 1.5 to 60 mg of glycyrrhizic acid or glycyrrhetinic acid is processed into a dosage form of the present invention which is administered four times a day; more preferably, it contains 3 to 40 mg of licorice.
  • the raw material of acid or glycyrrhetinic acid is prepared into a medicament of the present invention in a dosage form taken four times a day.
  • the medicament of the present invention may contain a raw material such as a pharmaceutically acceptable carrier or an additive, and is processed into an oral medicament for treating depression in the present invention.
  • the raw material according to the present invention is processed into a health food for treating depression according to the method for producing and manufacturing a health food.
  • FIG. 1 is a schematic flow chart of a method for preparing the drug of the embodiment 1 of the present invention.
  • Fig. 1 according to the GMP pharmaceutical standard method, 100 g of glycyrrhizic acid having a purity of 90% is prepared as a raw material, and 170 g of starch, lactose, silica, magnesium stearate and the like are added. After the agent was uniformly mixed, it was processed into a 9,000 capsule form (30 mg/granule containing 10 mg of glycyrrhizic acid).
  • the first embodiment of the present invention is for treating an oral or health food for depression.
  • FIG. 2 is a schematic flow chart of a method for preparing the drug of Example 2 of the present invention.
  • 10 kg of licorice is crushed, firstly immersed in water at room temperature, extracted by water extraction and alcohol precipitation, and then the extracted supernatant is concentrated and dried to obtain 2.1 kg of glycyrrhizic acid-containing extract.
  • the raw material containing the medicament of the present invention containing 0.23 kg of glycyrrhizic acid (the purity of glycyrrhizic acid in the extract is 11%) is detected by a high performance liquid chromatography instrument, and 2.5 kg of an auxiliary material such as starch, lactose and silica is added and mixed with the extract.
  • the second embodiment of the present invention which is processed into a 11,500 capsule dosage form (400 mg capsule containing 20 mg of glycyrrhizic acid), is used for the treatment of oral medication or health food for depression.
  • FIG. 3 is a schematic flow chart of a method for preparing the drug of the embodiment 3 of the present invention.
  • Fig. 3 according to the GMP pharmaceutical standard method, 200 g of glycyrrhizic acid having a purity of 96% is prepared as a raw material, and 280 g of an auxiliary material such as starch, lactose, silica, magnesium stearate, and the like are added.
  • the preparation is processed into an 8,000 tablet dosage form (60 mg/granule containing 24 mg of glycyrrhizic acid).
  • the third embodiment of the present invention is an oral medicine or health food for treating depression.
  • FIG. 4 is a schematic flow chart of a method for preparing the drug of the fourth embodiment of the present invention.
  • 100 g of glycyrrhetinic acid having a purity of 96% is prepared according to GMP pharmaceutical standards, and 140 g of starch, lactose, silica, strontium stearate and other excipients and excipients are added.
  • 140 g of starch, lactose, silica, strontium stearate and other excipients and excipients are added.
  • processed into a 8,000 tablet dosage form (30 mg / granule containing 12 mg of glycyrrhetinic acid).
  • the fourth embodiment of the invention is used for treating oral or health food for depression.
  • FIG. 5 is a schematic flow chart of a method for preparing the drug of Example 5 of the present invention.
  • 100 g of glycyrrhizic acid having a purity of 96% is prepared as a raw material, and 260 g of an auxiliary material such as starch, lactose, silica, magnesium stearate, and the like are added.
  • the preparation is processed into a 12,000 tablet dosage form (30 mg/granule containing 8 mg of glycyrrhizic acid).
  • the fifth embodiment of the present invention is an oral medicine or health food for treating depression.
  • FIG. 6 is a schematic flow chart of a method for preparing the drug of Example 6 of the present invention.
  • Fig. 6 according to the GMP pharmaceutical standard method, 50 g of glycyrrhetinic acid having a purity of 96% is prepared as a raw material, and 190 g of starch, lactose, silica, magnesium stearate and the like are added.
  • the sixth embodiment of the present invention is an oral or health food for treating depression.
  • ICR mice male, weighing 22.0 ⁇ 2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.
  • Example 3 Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.
  • Example 3 Large dose: 16 mg/kg/d, medium dose: 8 mg/kg/d and small dose: 4 mg/kg/d.
  • mice were randomized into groups of 10: 1 Example 3 high dose group (16 mg/kg, PO, 7d); 2 Example 3 medium dose group (8 mg/kg, PO, 7d) 3 Example 3 Low-dose group (4 mg/kg, PO, 7d); 4 paroxetine group (3 mg/kg, PO, 7d); 5 saline group (PO).
  • a tail suspension experiment was performed 1 hour after the last administration.
  • the tail of the mouse (1 cm from the tip of the tail) was adhered to the 5 cm wooden strip with a tape on the head for 6 minutes, and the immobility time of the mouse within 5 minutes after the recording was recorded.
  • Example 3 of the present invention has an anti-experimental depression function.
  • ICR mice male, weighing 22.0 ⁇ 2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.
  • Example 3 Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.
  • thermometer GM222 type electronic thermometer, stopwatch.
  • Example 3 Large dose: 16 mg/kg/d, medium dose: 8 mg/kg/d and small dose: 4 mg/kg/d.
  • mice were randomly divided into groups of 10: 1 Example 3 large dose group (16 mg kg, PO, 7d); 2 Example 3 medium dose group (8 mg/kg, PO, 7d); 3 Example 3 Small dose group (4 mg / kg, PO, 7d administration); 4 paroxetine group (3 mg / kg, PO, 7d administration); 5 saline group (PO).
  • the anus temperature of the mice was measured 1 hour after the administration on the 8th day, and then the reserpine 2 mg/kg was intraperitoneally injected, and the anal temperature of the mice was measured 4 hours after the injection of reserpine.
  • the depth and time of insertion of the thermometer into the anus of the mouse were consistent at each temperature measurement.
  • Example 3 Large dose group 10 1.85 ⁇ 1.01** Example 3 Medium dose group 10 2.05 ⁇ 1.03** Example 3 Low dose group 10 3.30 ⁇ 0.69 Note: Compared with the model group * P ⁇ 0.05 **P ⁇ 0.01
  • Example 3 of the present invention has an anti-experimental depression function.
  • ICR mice male, weighing 22.0 ⁇ 2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.
  • Example 4 Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.
  • Example 4 Large dose: 10 mg/kg/d, medium dose: 5 mg/kg/d and small dose: 2.5 mg/kg/d.
  • mice were randomly divided into groups of 10: 1 Example 4 large dose group (10 mg/kg, PO, 7d); 2 Example 4 dose group (5 mg / kg, PO, 7d) 3 Example 4 Low-dose group (2.5 mg/kg, PO, 7d); 4 paroxetine group (3 mg kg, PO, 7d); 5 saline group (PO).
  • a tail suspension experiment was performed 1 hour after the last administration.
  • the tail of the mouse (1 cm from the tip of the tail) was adhered to a 5 cm-long wooden strip with a tape on the head for 6 minutes, and the immobility time of the mouse within 5 minutes after the recording was recorded.
  • Example 4 of the present invention has an anti-experimental depression function.
  • ICR mice male, weighing 22.0 ⁇ 2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.
  • Example 4 Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.
  • thermometer GM222 type electronic thermometer, stopwatch.
  • Example 4 Large dose: 10 mg/kg d, medium dose: 5 mg/kg/d, small dose: 2.5 mg/kg/diens 4.5 Experimental methods and results
  • mice were randomized into groups of 10: 1 Example 4 large dose group (10 mg/kg, PO, 7d); 2 Example 4 medium dose group (5 mg/kg, PO, 7d) 3 Example 4 Low-dose group (2.5 mg/kg, PO, 7d); 4 paroxetine group (3 mg/kg, PO, 7d); 5 saline group (PO).
  • the anus temperature of the mice was measured 1 hour after the administration on the 8th day, and then the reserpine 2 mg/kg was intraperitoneally injected, and the anal temperature of the mice was measured 4 hours after the injection of reserpine.
  • the depth and time of insertion of the thermometer into the anus of the mouse were consistent at each temperature measurement.
  • Example 4 of the present invention has an anti-experimental depression function. Modifications, equivalent changes and modifications are still within the scope of the technical solutions of the present invention.
  • the oral drug for treating depression according to the present invention may contain a pharmaceutically acceptable additive
  • the oral medicament for treating depression according to the present invention can be processed into various conventionally known dosage forms such as powders, capsules, tablets, and the like;
  • the oral medicament for treating depression according to the present invention can be used for the treatment of health food for depression.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique orale ou un aliment naturel pour le traitement de la barythymie dont la préparation est caractérisée par l'utilisation d'acide glycyrrhizinique ou d'acide glycyrrhétinique en tant que matières premières.
PCT/CN2007/003388 2007-11-30 2007-11-30 Composition pharmaceutique orale pour le traitement de la barythymie Ceased WO2009070917A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/003388 WO2009070917A1 (fr) 2007-11-30 2007-11-30 Composition pharmaceutique orale pour le traitement de la barythymie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/003388 WO2009070917A1 (fr) 2007-11-30 2007-11-30 Composition pharmaceutique orale pour le traitement de la barythymie

Publications (1)

Publication Number Publication Date
WO2009070917A1 true WO2009070917A1 (fr) 2009-06-11

Family

ID=40717250

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/003388 Ceased WO2009070917A1 (fr) 2007-11-30 2007-11-30 Composition pharmaceutique orale pour le traitement de la barythymie

Country Status (1)

Country Link
WO (1) WO2009070917A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019070417A1 (fr) * 2017-10-04 2019-04-11 Harald Murck Traitement contre la dépression réfractaire aux autres thérapies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1416881A (zh) * 2002-11-27 2003-05-14 北京中医药大学 一种抗抑郁的药物组合物及其制备方法
CN1449761A (zh) * 2002-04-10 2003-10-22 吉林天药科技股份有限公司 一种解痉、镇痛药及制备方法
CN1686514A (zh) * 2005-03-21 2005-10-26 广西南宁邕江药业有限公司 治疗焦虑症、抑郁症的中药制剂及其生产方法
CN1836687A (zh) * 2005-03-25 2006-09-27 北京欧纳尔生物工程技术有限公司 治疗抑郁症的药物组合物及其制法
CN1839854A (zh) * 2005-04-01 2006-10-04 安徽省现代中药研究中心 甘草甜素新型软胶囊及其制备工艺
CN1879641A (zh) * 2005-06-18 2006-12-20 安徽省现代中药研究中心 甘草甜素分散片及其制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1449761A (zh) * 2002-04-10 2003-10-22 吉林天药科技股份有限公司 一种解痉、镇痛药及制备方法
CN1416881A (zh) * 2002-11-27 2003-05-14 北京中医药大学 一种抗抑郁的药物组合物及其制备方法
CN1686514A (zh) * 2005-03-21 2005-10-26 广西南宁邕江药业有限公司 治疗焦虑症、抑郁症的中药制剂及其生产方法
CN1836687A (zh) * 2005-03-25 2006-09-27 北京欧纳尔生物工程技术有限公司 治疗抑郁症的药物组合物及其制法
CN1839854A (zh) * 2005-04-01 2006-10-04 安徽省现代中药研究中心 甘草甜素新型软胶囊及其制备工艺
CN1879641A (zh) * 2005-06-18 2006-12-20 安徽省现代中药研究中心 甘草甜素分散片及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019070417A1 (fr) * 2017-10-04 2019-04-11 Harald Murck Traitement contre la dépression réfractaire aux autres thérapies

Similar Documents

Publication Publication Date Title
Ye et al. Anoectochilus roxburghii: A review of its phytochemistry, pharmacology, and clinical applications
EP2491934B1 (fr) Utilisation d'albiflorine en tant qu'antidépresseur
US9603866B2 (en) Anti-fatigue composition, formulation and use thereof
WO2009070915A1 (fr) Compositions pharmaceutiques destinées à traiter la dépression et l'anxiété
RU2395293C2 (ru) Фармацевтическая композиция для лечения депрессии и способ ее получения
CN110035763A (zh) 用于治疗寄生虫病的组合物及其方法
WO2009070921A1 (fr) Médicament antidépresseur à base de matériaux d'amp cylique de jujube
WO2009070924A1 (fr) Compositions pharmaceutiques avec mécanisme à rétroaction par récepteur multi-cible pour le traitement de la dépression
CN101288761A (zh) 一种治疗抑郁症的中药制剂及其制备方法
WO2009070917A1 (fr) Composition pharmaceutique orale pour le traitement de la barythymie
WO2009070922A1 (fr) Compositions pharmaceutiques pour le traitement de l'anxiété
CN101450063A (zh) 治疗忧郁症的口服药物
CN104548020B (zh) 一种药物组合物在制备治疗老年痴呆症药物中的用途
TWI400078B (zh) 以甘草、大棗為原料的治療憂鬱症的藥物組合物
TWI453027B (zh) 主功效成分為大棗環腺苷單磷酸之藥物作為治療憂鬱症的用途
CN101450121A (zh) 以甘草、大枣为原料的治疗忧郁症的药物组合物及其制法
WO2009070923A1 (fr) Composition pharmaceutique pour le traitement de la dépression et sa méthode de préparation
TWI394576B (zh) 以人參、大棗為原料的治療憂鬱症的藥物組合物及其製法
RU2456014C2 (ru) ЛЕКАРСТВЕННОЕ СРЕДСТВО ОТ МЕЛАНХОЛИИ, ПОЛУЧЕННОЕ С ИСПОЛЬЗОВАНИЕМ МАТЕРИАЛОВ С сАМР ЖУЖУБА
CN101450120A (zh) 以人参、大枣为原料的治疗忧郁症的药物组合物及其制备方法
WO2009070916A1 (fr) Composition pharmaceutique pour le traitement de la dépression et son procédé de préparation
CN101450062A (zh) 多靶标受体后作用机制用于治疗忧郁症的药物组合物
TW200922610A (en) Oral medicine for treating depression
TW200920391A (en) Multi-target post-receptor action used in pharmaceutical composition for depression treatment
CN1686514A (zh) 治疗焦虑症、抑郁症的中药制剂及其生产方法

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07845751

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07845751

Country of ref document: EP

Kind code of ref document: A1